4.4 Article

Toll-Like Receptor 4 Signaling Contributes to Paclitaxel-Induced Peripheral Neuropathy

Journal

JOURNAL OF PAIN
Volume 15, Issue 7, Pages 712-725

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.jpain.2014.04.001

Keywords

Neuropathy; DRG; spinal cord; TLR4; MyD88; TRIF; LPS-RS

Funding

  1. National Institutes of Health [NS 046606]
  2. National Cancer Institute [CA124787]

Ask authors/readers for more resources

This paper tests the contribution of the toll-like receptors, TLR4 in particular, in the initiation and maintenance of paclitaxel-related chemotherapy-induced peripheral neuropathy. TLR4 and its immediate downstream signaling molecules myeloid differentiation primary response gene 88 (MyD88) and toll/interieukin 1 receptor domain-containing adapter-inducing interferon-beta (TRIF) were found to be increased in the dorsal root ganglion (DRG) using Western blot by day 7 of paclitaxel treatment. The behavioral phenotype, the increase of both TLR4 and MyD88, was blocked by cotreatment with the TLR4 antagonist lipopolysaccharide-Rhodobacter sphaeroides during chemotherapy. A similar, but less robust, behavioral effect was observed using intrathecal treatment of MyD88 homodimerization inhibitory peptide. DRG levels of TLR4 and MyD88 reduced over the next 2 weeks, whereas these levels remained increased in spinal cord through day 21 following chemotherapy. lmmunohistochemical analysis revealed TLR4 expression in both calcitonin generelated peptide-positive and isolectin B4-positive small DRG neurons. MyD88 was only found in calcitonin gene-related peptide-positive neurons, and TRIF was found in both calcitonin gene-related peptide-positive and isolectin B4-positive small DRG neurons as well as in medium- and large-size DRG neurons. In the spinal cord, TLR4 was only found colocalized to astrocytes but not with either microglia or neurons. Intrathecal treatment with the TLR4 antagonist lipopolysaccharide-R. sphaeroides transiently reversed preestablished chemotherapy-induced peripheral neuropathy mechanical hypersensitivity. These results strongly implicate TLR4 signaling in the DRG and the spinal cord in the induction and maintenance of paclitaxel-related chemotherapy-induced peripheral neuropathy. Perspective: The toll-like receptor TLR4 and MyD88 signaling pathway could be a new potential therapeutic target in paditaxel-induced painful neuropathy. (C) 2014 by the American Pain Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available